Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Apr 22, 2026
- Pharmaceuticals
- R&D
Roche’s Announcement Regarding New Data of Enspryng for Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
TOKYO, April 22, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a media release today, regarding new data from the METEOROID study of Enspryng® (generic name: satralizumab) for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The data were presented on April 21 at the 2026 American Academy of Neurology Annual Meeting in Chicago.
Please refer to the link below for details of the media release:
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
https://www.roche.com/media/releases/med-cor-2026-04-21b
Trademarks used or mentioned in this release are protected by laws.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Naoki Kouzai
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp